Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AZTA 
Azenta Inc (AZTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: AZTA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $35.17
1 Year Target Price $35.17
| 1 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.79% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.35B USD | Price to earnings Ratio - | 1Y Target Price 35.17 |
Price to earnings Ratio - | 1Y Target Price 35.17 | ||
Volume (30-day avg) 7 | Beta 1.3 | 52 Weeks Range 23.91 - 55.63 | Updated Date 11/7/2025 |
52 Weeks Range 23.91 - 55.63 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-11 | When Before Market | Estimate 0.2 | Actual - |
Profitability
Profit Margin -16.68% | Operating Margin (TTM) 0.03% |
Management Effectiveness
Return on Assets (TTM) -1.6% | Return on Equity (TTM) -9.15% |
Valuation
Trailing PE - | Forward PE 29.07 | Enterprise Value 1177264034 | Price to Sales(TTM) 2.03 |
Enterprise Value 1177264034 | Price to Sales(TTM) 2.03 | ||
Enterprise Value to Revenue 1.76 | Enterprise Value to EBITDA 104.52 | Shares Outstanding 45839728 | Shares Floating 40481981 |
Shares Outstanding 45839728 | Shares Floating 40481981 | ||
Percent Insiders 1.8 | Percent Institutions 116.56 |
Upturn AI SWOT
Azenta Inc
Company Overview
History and Background
Azenta, Inc. (formerly Brooks Automation) was founded in 1978. Initially focused on robotics for semiconductor manufacturing, it evolved to provide automation and cryogenic solutions for life sciences. The company rebranded as Azenta in 2021 after divesting its automation solutions business.
Core Business Areas
- Life Sciences: Provides sample management and automation solutions for the life sciences industry, including genomic services and cell therapy products.
Leadership and Structure
The CEO of Azenta, Inc. is Steve Schwartz. The company has a typical corporate structure with departments for sales, marketing, R&D, operations, and finance, reporting to a board of directors.
Top Products and Market Share
Key Offerings
- Sample Management Solutions: Automated storage systems, cryogenic freezers, and related consumables for biological samples. Exact market share data unavailable, but competes with Thermo Fisher Scientific and BioLife Solutions. Generates significant revenue, a key growth product.
- Genomic Services and Products: Services include gene synthesis, sequencing, and cell line engineering. Cell therapy services too. Competes with companies like Illumina and Thermo Fisher Scientific. Generates significant revenue, a key growth product.
Market Dynamics
Industry Overview
The life sciences industry is experiencing rapid growth, driven by advancements in genomics, personalized medicine, and cell therapies. Automation and sample management are becoming increasingly critical for research and development.
Positioning
Azenta is positioned as a provider of automation and sample management solutions in the life sciences space, particularly in genomics and cell therapy. Its competitive advantages include its established reputation, broad product portfolio, and focus on innovation.
Total Addressable Market (TAM)
The total addressable market for life sciences automation and sample management is estimated to be in the billions of dollars. Azenta aims to capture a significant share through innovation and expansion in key growth areas like cell therapy.
Upturn SWOT Analysis
Strengths
- Strong market position in sample management
- Comprehensive product portfolio
- Established customer base
- Focus on innovation
Weaknesses
- Dependence on life sciences industry
- Integration risks from acquisitions
- Competition from larger players
Opportunities
- Growing demand for automation in life sciences
- Expansion into new geographic markets
- Development of new products and services
- Partnerships and collaborations
Threats
- Economic downturn
- Increased competition
- Technological changes
- Regulatory changes
Competitors and Market Share
Key Competitors
- TMO
- ILMN
- WAT
Competitive Landscape
Azenta faces competition from larger and smaller players in the life sciences automation and sample management market. It differentiates itself through its integrated solutions and focus on innovation.
Major Acquisitions
Bioxis
- Year: 2021
- Acquisition Price (USD millions): 85
- Strategic Rationale: Expanded cell therapy services portfolio.
Growth Trajectory and Initiatives
Historical Growth: Azenta has grown organically and through acquisitions, expanding its product portfolio and customer base.
Future Projections: Analysts expect Azenta to continue to grow in the coming years, driven by the increasing demand for automation in life sciences. Revenue Growth Estimates (%): [8, 10, 12]
Recent Initiatives: Recent initiatives include acquisitions to expand offerings and investments in R&D to develop new products.
Summary
Azenta is a key player in the life sciences automation and sample management space. It has a solid market position and comprehensive product portfolio. However, it faces competition from larger players and integration risks from acquisitions. The company's focus on innovation and expansion into new markets provides a strong growth opportunity.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Financial metrics are estimates and based on available information and should be verified. Market share data is approximate. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Azenta Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 1995-02-02 | President, CEO & Director Mr. John P. Marotta | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 3000 | Website https://www.azenta.com |
Full time employees 3000 | Website https://www.azenta.com | ||
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates through three reportable segments: Sample Management Solutions, Multiomics, and B Medical Systems. The Sample Management Solutions segment provides sample management products and solutions, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, synthesis editing, and related services. The B Medical Systems segment manufactures and distributes temperature-controlled storage and transportation solutions to governments, health institutions, and non-government organizations. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.